Patent · US Active

Cysteine linked nanobody dimers

US11426468B2 · kind B2 · utility

3Cited by

4References

6Claims

0Family size

Assignee

Ablynx N.V. · BE

Inventors

Daniel Janssen · Puurs, BE
Peter Schotte · Zevergem, BE
Francis Descamps · Roeselare, BE
Carlo Boutton · Wielsbeke, BE
Peter Casteels · Bambrugge, BE

Key dates

Filing date	Dec 18, 2015
Grant date	Aug 30, 2022
Priority date	—
Expiry date	Jan 14, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.